Janux Therapeutics, Inc. (JANX)
US — Healthcare Sector
Automate Your Wheel Strategy on JANX
With Tiblio's Option Bot, you can configure your own wheel strategy including JANX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JANX
- Rev/Share 0.024
- Book/Share 15.7449
- PB 1.7523
- Debt/Equity 0.0232
- CurrentRatio 35.8624
- ROIC -0.1444
- MktCap 1659448833.0
- FreeCF/Share -1.1511
- PFCF -23.2426
- PE -16.7941
- Debt/Assets 0.0221
- DivYield 0
- ROE -0.1018
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JANX | Barclays | -- | Overweight | -- | $47 | Sept. 17, 2025 |
| Initiation | JANX | Truist | -- | Buy | -- | $100 | Sept. 10, 2025 |
| Initiation | JANX | Stifel | -- | Buy | -- | $45 | Sept. 10, 2025 |
| Initiation | JANX | Guggenheim | -- | Buy | -- | $72 | Sept. 4, 2025 |
| Initiation | JANX | Piper Sandler | -- | Overweight | -- | $42 | Aug. 19, 2025 |
| Initiation | JANX | Raymond James | -- | Outperform | -- | $65 | July 11, 2025 |
| Reiterated | JANX | H.C. Wainwright | -- | Buy | $63 | $70 | Dec. 3, 2024 |
| Reiterated | JANX | BTIG Research | -- | Buy | $82 | $100 | Dec. 3, 2024 |
| Initiation | JANX | Stifel | -- | Buy | -- | $70 | Sept. 6, 2024 |
News
Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last?
JANX
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Janux Therapeutics (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?
JANX
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Janux Therapeutics (JANX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
About Janux Therapeutics, Inc. (JANX)
- IPO Date 2021-06-11
- Website https://www.januxrx.com
- Industry Biotechnology
- CEO David Alan Campbell
- Employees 91
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.